Key Highlights

  • VEEA Inc. Swapped demand notes worth $4,132,910.49 for 41,329 Series A‑1 preferred shares priced at $100 each.
  • Each preferred share’s conversion amount is derived by dividing the $100 per share stated value by $0.31.

VEEA Inc. (NASDAQ: VEEA) announced a material agreement that transforms outstanding demand notes into equity and warrant instruments. The Note Conversion Agreement, executed on June 25 2026, replaces debt with preferred stock and long‑dated purchase rights, thereby reshaping the company’s financing profile. This conversion removes the associated principal and accrued interest from VEEA’s balance sheet.

Each warrant is issued with a par value of $0.0001 per share and an exercise price fixed at $0.31 per share. The warrants become exercisable on January 1 2027 and remain outstanding through June 25 2031.

Conversion Mechanics

Each Series A‑1 preferred share may be converted into Common Stock in accordance with the conversion formula set forth in the Note Conversion Agreement. The formula divides the $100.00 per share stated value by the $0.31 exercise price, establishing a conversion capacity that aligns with the aggregate of 13,331,969 Common Warrants.

Registration Rights and Exempt Offering

The agreement provides NLabs with registration rights for any Common Stock that may arise from converting the preferred shares.

Legal Attachments

The terms governing the preferred stock are detailed in a Certificate of Designation filed with the Delaware Secretary of State.

Impact on Capital Structure

By converting $4,132,910.49 of debt into equity, VEEA reduces its leverage while adding a convertible preferred class and a substantial warrant pool. This restructuring may improve liquidity and align shareholder interests, although the ultimate dilution effect will depend on the future exercise of the warrants.

Sector Context

VEEA operates within the rapidly evolving biotechnology sector, where companies frequently balance research‑intensive cash needs against capital efficiency. The use of convertible preferred instruments and long‑dated warrants is a common strategy for biotech firms seeking to preserve cash for clinical programs while offering investors downside protection and upside participation. This transaction aligns VEEA with peers that have leveraged similar financing structures to fund pipeline development and expand market presence.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.